N. Ford

发表

Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?

N. Ford, 2009, Journal of clinical pharmacology.

Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography.

N. Alpert, A. Fischman, B. Christian, 1996, The Journal of pharmacology and experimental therapeutics.

Comparison of the Steady-State Pharmacokinetics of Fosinopril, Lisinopril and Enalapril in Patients with Chronic Renal Insufficiency

R. Cutler, R. J. Parmer, D. Sica, 1991, Clinical pharmacokinetics.

Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation

D. Abernethy, N. Ford, J. Barbey, 2001, Clinical pharmacology and therapeutics.

Pharmacokinetics and Pharmacodynamics of Avitriptan in Patients With Migraine After Oral Dosing

N. Cutler, N. Ford, J. Sramek, 1998, Headache.

A Double-Blind, Randomized, Crossover Assessment of Blood Pressure Following Administration of Avitriptan, Sumatriptan, Or Placebo To Patients with Mild To Moderate Hypertension

N. Cutler, N. Ford, J. Sramek, 1999, Cephalalgia : an international journal of headache.

The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway

N. Ford, 2016, Journal of clinical pharmacology.

Clopidogrel: What Is a Cardiologist to Do?

N. Ford, 2014, Journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of Irbesartan in Patients with Hepatic Cirrhosis

K. Lasseter, N. Ford, R. Raymond, 1998, Journal of clinical pharmacology.

Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men.

D. Webb, D. Newby, M. Palmisano, 2005, British journal of clinical pharmacology.

A receptor selective antagonist BMS-193884 in healthy men

D. Webb, D. Newby, M. Palmisano, 2005 .

An Opioid-benzodiazepine Interaction: Benzodiazepines as Opioids?

N. Ford, 2018 .

Effect of Nifedipine on the Steady-State Pharmacokinetics and Pharmacodynamics of Irbesartan in Healthy Subjects

N. Ford, M. Marino, H. Uderman, 1998, Journal of cardiovascular pharmacology and therapeutics.

Defining the Maximum Tolerated Dose: Investigator, Academic, Industry and Regulatory Perspectives

D. Greenblatt, L. Lesko, R. Williams, 1997, Journal of clinical pharmacology.

Clinically Significant Cytochrome P‐450 Drug Interactions—A Comment

D. Sonnichsen, N. Ford, D. Sonnichsen, 1998, Pharmacotherapy.

Pharmacokinetics and Pharmacodynamics of Irbesartan in Healthy Subjects

N. Ford, M. Marino, H. Uderman, 1998, Journal of clinical pharmacology.

Effects of ceronapril alone or in combination with alcohol on psychomotor performance in healthy volunteers: a placebo-controlled, crossover study

J. Vanakoski, N. Ford, L. Näveri, 2001 .

Fosinopril monotherapy: Relationship between blood pressure reduction and time of administration

N. Ford, J. Herron, I. E. Fulmor, 1993, Clinical cardiology.

The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis

D. Sica, N. Ford, T. Gehr, 1997, Clinical pharmacology and therapeutics.

Effect of Hydrochlorothiazide on the Pharmacokinetics and Pharmacodynamics of the Angiotensin II Blocker Irbesartan

K. Lasseter, N. Ford, R. Raymond, 1997 .

Single‐Dose and Steady‐State Pharmacokinetics of Fosinopril and Fosinoprilat in Patients with Hepatic Impairment

K. Lasseter, J. Manning, N. Ford, 1995, Journal of clinical pharmacology.

Measurement of 2,4-toluenediamine in urine and serum samples from women with Même or Replicon breast implants.

M. Cohen, N. Ford, P. Gale, 1997, Plastic and reconstructive surgery.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis

J. T. ten Berg, H. Bouman, N. Ford, 2011, BMJ : British Medical Journal.

Invasive Pharmacodynamics of Fosinopril in Patients with Congestive Heart Failure

K. Hui, N. Ford, R. Smith, 1995, Journal of clinical pharmacology.

The Pharmacokinetics of Irbesartan in Hypertensive Children and Adolescents

Kim G. Adcock, John T. Wilson, N. Ford, 2001, Journal of clinical pharmacology.

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.

D. Berry, F. Sacks, C. Hennekens, 2003, Archives of internal medicine.

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.

M. Jemal, N. Ford, B. Swanson, 2003, British journal of clinical pharmacology.

Clopidogrel, CYP2C19, and a Black Box

N. Ford, D. Taubert, 2013, Journal of clinical pharmacology.

Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension

K. Lasseter, J. Manning, N. Ford, 1999, Journal of cardiovascular pharmacology and therapeutics.

The pharmacokinetics of pravastatin in patients on chronic hemodialysis

D. Sica, N. Ford, T. Gehr, 1997, European Journal of Clinical Pharmacology.

The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway

N. Ford, 2016, Journal of clinical pharmacology.

ACE inhibitor lacks acute effect on cognition or brain blood flow in alzheimer's disease

M. Weiner, F. Bonte, D. Svetlik, 1992 .